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Albeit a very large number of experiments have assessed the impact of various substrates on liver regeneration after partial
hepatectomy, a limited number of clinical studies have evaluated artificial nutrition in liver resection patients. This is a peculiar
topic because many patients do not need artificial nutrition, while several patients need it because of malnutrition and/or
prolonged inability to feeding caused by complications. The optimal nutritional regimen to support liver regeneration, within
other postoperative problems or complications, is not yet exactly defined. This short review addresses relevant aspects and potential
developments in the issue of postoperative parenteral nutrition after liver resection.
1. Introduction
Although there has been a plethora of animal studies on
factors and nutritional substrates supporting or inhibiting
liver regeneration after liver resection (LR), a limited number
of human studies has addressed parenteral or enteral nutri-
tion in LR. This is a peculiar topic. Indeed, most surgeons
do not give particular value to substrate infusion after LR,
because most patients can resume an oral diet within the
3rd or the 4th postoperative day, so that starvation does not
become an issue. Therefore, it is difficult to find evidence-
based information or guidelines on this topic.
On the other hand, major LR, compared to other ab-
dominal operations, is characterized by a specific need for
substrate for liver regeneration, and in extreme cases also
by competition for substrate to simultaneously support
acute phase response, liver regeneration, and host defence
if postoperative sepsis occurs [1]. Nutritional support may
become an issue not only when the resumption of feeding is
prevented by complications and prolonged illness, but also
soon postoperatively in malnourished patients with a high
risk of complications.
2. Randomized Studies
Among the clinical studies which have addressed artificial
nutrition in LR in previous decades, there are also ran-
domized protocols comparing parenteral to enteral nutrition
after LR, or even preoperatively [2–7]. The results are
relevant, and, in particular, one of them clearly shows that
artificial nutrition improves the outcome of hepatectomy
in cirrhotic patients [2]. However again, these studies
are not sufficient to establish realistic indications. Firstly,
preoperative artificial nutrition does not comply with the
current practice of patient management and hospitaliza-
tion. Secondly, as already mentioned, after surgery most
patients rapidly restart oral feeding without a clear need
for artificial nutrition. Thirdly, when artificial nutrition is
indicated because of prolonged inability to feeding, there
are often various combinations of malnutrition, acute liver
dysfunction, and sepsis whose complex management largely
overcomes that of routinely recovering LR patients. Up until
now, there are no guidelines specifically considering the
need to support liver regeneration within other problems
and complications, and nutritional prescriptions are still
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empirically tailored. Although our experience is mostly based
on parenteral nutrition, even an evidence-based choice of
enteral or parenteral nutrition remains an unsolved issue.
The reasonable option is to take advantage of both, when
artificial nutrition is indicated, as the former maintains
bowel integrity and gut wall barrier function, while the latter
allows the obtainment of full-regimen support and fluid-
electrolyte balance, which may not always be attainable by
enteral nutrition alone.
3. Patients with Malnutrition
Important malnutrition [8] may be a reason to delay major
surgery for a few weeks if a preoperative improvement in
nutritional state is achievable. For instance, malnutrition
is sometimes associated with severe obstructive jaundice in
patients with hilar cholangiocarcinoma (Klatskin tumor). In
these cases the postponement of major hepatectomy may
simultaneously be dictated by the need for biliary drainage
to treat jaundice, for portal embolization to hypertrophy
future remnant liver, and for the improvement of nutritional
state [9]. Furthermore, given the high risk of complications
and prolonged illness, full-regimen parenteral nutrition is
started soon postoperatively. Similar considerations apply
to cirrhotic patients after major hepatectomy, in whom
liver regeneration and recovery may be more dependent on
appropriate nutritional support [10].
4. Choice of Substrates
We perform at present about 150 LR per year, and it has
long been our standard to administer to all patients from
the 1st p.o. day a dose of at least 2.0–2.5 g/kg/day dextrose
and 0.8–1.0 g/kg/day amino acids (35 to 50% branched chain
amino acids) [9, 11]. This is to moderate the catabolic drive
(glycogenolysis, and proteolysis for gluconeogenesis) and to
provide some support for liver regeneration, as glucose alone,
unless associated with other substrates, does not seem to
support hepatic regeneration [12–14]. Intravenous infusions
are withdrawn with the resumption of oral feeding, in
general within the 3rd or 4th postoperative day.
If a complication prevents feeding, the regimen is aug-
mented to full-dose parenteral nutrition providing 30 to
35Kcal/kg/day (about 50% dextrose and 50% fat, preferen-
tially using a mixed fat emulsion with 50% medium chain
and 50% long chain triglycerides) and about 1.5 g/kg/day
amino acids (35 to 50% branched chain amino acids) [9, 11].
A similarly robust support is started soon postoperatively in
patients with malnutrition and/or an expected greater risk
of complications. This regimen is similar to independently
developed regimens adopted for LR in liver cirrhosis, in other
patients after major LR and in living donors for liver trans-
plantation [10, 15–17]. Apart from the favourable properties
of medium chain triglycerides [10, 18], we simply consider
their use as a means of distributing the calorie load over three
different substrates (dextrose, long chain, and medium chain
triglycerides) therefore avoiding problems associated with
high doses of single substrates (difficult glycemic control,
excessive load of linoleic acid, etc.). The supply of high doses
of branched chain amino acids (BCAAs), within the total
amino acid dose, is to take advantage of their moderate
anticatabolic and proanabolic effect, and of other favourable
properties [10, 19, 20]; there is also long-lasting consensus
on their effects in experimental studies on liver regeneration
[13, 14, 21]. Of note, BCAA or BCAA-enriched amino acid
solutions are not particularly expensive in Italy.
Appropriate amounts of electrolytes, vitamins, and trace
elements are obviously needed. Within micronutrients,
particular attention is given to phosphate supply. It is unclear
whether early severe hypophosphatemia after LR depends
on increased metabolic consumption, urinary loss, or other
mechanisms [22–24]. Anyhow it seems to predict a higher
risk of complications, and there is some evidence that
phosphate replacement is associated with better outcome,
also in living donors for liver transplantation [22, 25]; this
needs to be confirmed in further studies.
5. Complications
The most common complications after LR are transient
liver insufficiency and sepsis. Transient liver insufficiency in
itself might not be a reason to modify nutritional support.
However, the presence of encephalopathy may involve the
reduction or interruption of fat infusion, which can worsen
this symptom [18, 26]. A relatively high total amino acid
dose (1.0–1.5 g/kg/day) in the presence of liver insuffi-
ciency should not be of concern if this include a large
percentage of BCAAs. BCAAs do not represent additional
burden for the liver because they are primarily metabolized
in other tissues; thereafter, the liver advantageously uses
their metabolites [19, 20]. High BCAA doses maintain a
high plasma BCAA/aromatic amino acid ratio and better
control this component of hepatic encephalopathy, maintain
some anticatabolic and proanabolic drive, improve energy
metabolism, and have other properties which can also
include a contribution to reducing ammonia levels [27].
Sometimes in severe encephalopathy there is a need to
infuse only BCAAs, interrupting the infusion of other amino
acids [28]. Simultaneous dextrose infusion may contribute
to increase the BCAA/aromatic amino acid ratio by reducing
the endogenous aromatic amino acid load from protein
catabolism, while cleaning of the bowel and/or manipulation
of its microbial flora reduce endogenous ammonia produc-
tion.
Unfortunately these supportive measures cannot be of
major help when very severe hepatic insufficiency occurs
from too small residual liver or other major complications
affecting its function. Despite occasional reports on major
benefits of nutrition [29], one cannot rely on nutrition to
postoperatively enhance function of a small residual liver.
The issue must be resolved in advance, by preoperative portal
embolization to hypertrophy future remnant liver, or by
excluding the patient from resection. In our policy future
remnant liver should at least be 25–30% in normal adults
and 45–50% in cirrhotic patients, with an intermediate
percentage in patients with steatosis or steatohepatitis from
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chemotherapy before LR for metastases, or in patients with
cholestatic liver. Hence, realistically parenteral nutrition after
LR can only represent a helpful supportive tool when tran-
sient liver insufficiency develops in spite of all precautions.
Liver resection predisposes to sepsis by a variety of
mechanisms, including the removal of liver cells involved
in host defence [9], and there is well-known synergism of
sepsis and liver dysfunction in determining a poor outcome
[9, 30, 31]. Of course, treatment of sepsis is the main target,
however, nutritional support also has a relevant role. Amajor
surgical procedure which is often associated with septic
complications is LR for hilar cholangiocarcinoma. When the
patients present with severe obstructive jaundice, there is a
need for preoperative biliary drainage which predisposes to
microbial contamination of the biliary tree, with a greater
risk of sepsis after surgery in a contaminated field. Because
surgery often consists of a major or extended hepatectomy,
sepsis is often overimposed on transient liver insufficiency
[9].
When sepsis develops, the treatment should not diverge
much from the common guidelines for sepsis. These include
the tailoring of dextrose load according to glucose intol-
erance, the supply of fat emulsions not containing large
amounts of the omega-6 polyunsaturated linoleic acid to
avoid excessive amplification of the inflammatory response,
and a daily dose of 1.5–2.0 g/kg amino acids (35 to 50%
BCAAs). We believe that the use of high-dose insulin to
allow large dextrose loads is unsafe in normal surgical wards,
because of the risk of hypoglycemic accidents. Reduction
of the linoleic acid dose is permitted by using mixed
emulsions with 50% long chain and 50% medium chain
triglycerides, or olive oil-based emulsions, while additional
fish oil emulsions may provide an integration of omega-3
polyunsaturated fatty acids. There are also newly available
mixed emulsions containing all these components together
(long chain, medium chain triglycerides, and fish oil, with or
without olive oil) although published experience on their use
in LR is lacking. The total calorie dose (dextrose + fat) should
be about 30 to 35 kcal/kg/day. With regard to the combined
use of enteral nutrition (whenever feasible) in sepsis, this
seems to enhance gut wall barrier function and moderate
inflammatory response, while in severe liver insufficiency
and encephalopathy enteral nutrition might not be desirable.
At any rate, the important concept to emphasize is that,
once infection appears, the clinical course could rapidly go
downhill. Therefore, parenteral nutrition should be given to
patients at risk immediately after LR. In addition, it should be
continued even when the patients have resumed oral feeding,
which may not be sufficient to cover metabolic demands in
the initial period. The patients at greater risk are those with
liver cirrhosis, major hepatectomy, and concomitant biliary
tract infection or bacterial colonization.
6. Biochemical Measurements
There is a well-known series of biochemical measurements
which are commonly performed after LR, or in complicated
cases undergoing parenteral nutrition, and do not deserve
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Figure 1: Patients on parenteral nutrition after LR. Within
the main group of measurements (encircled), there is general
reduction in plasma cholesterol compared to preoperative value,
with low-normal triglycerides. A: measurement with the lowest
cholesterol and highest triglyceride levels, without fat infusion,
signalling the transition of a septic patient to preterminal illness
and shock. B: measurements with less severe hypertriglyceridemia
signalling transient but reversible worsening of septic illness in two
patients undergoing fat infusion. C: measurements with increased
cholesterol associated with development of cholestasis in another
patient.
particular notes. Conversely the dosage of plasma cholesterol,
triglycerides, cholinesterase, and blood urea nitrogen deserve
some comment. Transient hypocholesterolemia is a normal
consequence of surgery, and after LR is mainly related to
extent of liver resection, severity of acute-phase response,
hemodilution from blood loss, and liver dysfunction, if
present. Normally hypocholesterolemia progressively recov-
ers. Persistent, or persistently severe hypocholesterolemia
after LR has a different relevance, because it is related to
sepsis or to a synergic combination of sepsis and liver
insufficiency and very poor prognosis [32, 33]. Of note,
cholestasis, if present, moderates the degree of hypoc-
holesterolemia. These concepts implicate that persistent
hypocholesterolemia after LR has very little to do with
nutritional state, or with the infusion of fat. Fat emulsions
contain only an irrelevant amount of cholesterol. Conversely,
serum triglyceride levels usefully reflect the plasma clearance
of the infused fat. In sepsis the observation of normal or
low triglycerides does not have particular relevance, while
hypertriglyceridemia may reflect both the worsening of the
septic state and/or excessive fat load compared to clearance
[33, 34]. Indeed, although in sepsis fat is a preferential
substrate, in extreme septic illness impaired fat clearancemay
develop, therefore, determining moderate-to-severe hyper-
triglyceridemia (Figure 1). The dosage of plasma butyryl-
cholinesterase (CHE) is another useful adjunct because
decreasing CHE, like decreasing cholesterol, may reflect both
severity of acute phase response (sepsis) and severity of liver
dysfunction [35], with a risk of poor outcome. The practical
implication is the need for the aggressive resolution of a
septic focus, if present. Of note, the transfusion of fresh
4 Journal of Nutrition and Metabolism
frozen plasma or blood can increase CHE independently of
the underlying condition. As in the case of cholesterol, the
anecdotal relationship between CHE and nutritional state
is lost in critical illness although CHE seems to maintain
some direct relationship with the amino acid dose [35].
Increased blood urea nitrogen with normal creatinine may
commonly reflect protein hypercatabolism (especially in
sepsis), bleeding in the gastrointestinal tract, and sometimes
renal dysfunction from hypovolemia. It may also reflect
increased exogenous amino acid dose; however, it is often
gratifying to observe a decrease in blood urea nitrogen,
for any given creatinine and amino acid dose, related to
increasing doses of dextrose and fat, therefore reflecting a
better use of amino acids for protein synthesis.
7. New and Related Interventions
Among other aspects, recent information is addressing the
benefits of perioperative dextrose and insulin administra-
tion in LR (starting already preoperatively) to maintain
hepatic glycogen stores; this seems to be associated with
better recovery of liver function and also protection from
ischemia/reperfusion injury [29, 36]. With regard to the
newly developed mixed fat emulsions with long chain,
medium chain triglycerides and fish oil, with or without
olive oil, it is very likely that LR patients can benefit
from each of these fat components while avoiding potential
harm from high doses of single fat substrates. As already
mentioned, evidence-based information is lacking, and
evaluation of these mixed emulsions in the clinical setting
has greater priority over ordinary comparisons between
the previously available and simpler emulsions. Finally,
with regard to BCAAs, other interesting aspects which
deserve mention, although beyond the topic of this short
review, are the reported benefits of preoperative oral BCAA
supplementation on the early response to LR [37], and the
better long term outcome associated with protracted oral
supplementation with BCAAs and carbohydrates, after LR
for cancer in cirrhotic patients [38].
In conclusion, parenteral nutrition in LR patients still
remains a poorly defined field. Firstly because most LR
patients only need some short-term and light parenteral sup-
port, while a formal parenteral nutrition regimen is required
in peculiar or complicated cases. Secondly because, despite
a plenitude of animal experiments, there is no evidence-
based data for the optimal combination of substrates to
support liver regeneration and liver function in the clinical
setting. This differs from the experimental setting. Indeed,
the ability of the liver to regenerate after resection in humans
depends on many factors such as the remnant liver size, the
quality of the liver remnant, the damage to the liver remnant
during and after surgery, concomitant sepsis, and bile duct
obstruction or damage. Hence, it is quite difficult to confirm
animal experimental findings in patients unless unified
groups of patients are included in the studies. Therefore,
guidelines remain relatively empirical, and the field remains
open to future and more specific investigations.
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